Danish biotech Curasight continues to advance its position in the rapidly growing radiopharmaceutical sector. To fuel its transition into a mature clinical-stage company, Curasight has secured a financing package comprising a directed share issue and a loan facility. The capital extends the company’s cash runway to the end of 2026, funding important value inflection points in clinical development for the next 12 months as well as supporting a broadening of the development program for brain cancer to include the US.

Read the full interview with CEO Ulrich Krasilnikoff at biostock.se:

Curasight funded to reach key clinical milestones

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock